Pharma Stability: Insights, Guidelines, and Expertise
ICH guidelines (Q1A to Q1E) define standard timepoints—0, 3, 6, 9, 12, 18, 24, 36 months—for long-term and accelerated stability studies. These timepoints drive critical decision-making regarding shelf life, storage labeling, and dossier submissions. Delays in achieving or documenting these timepoints can compromise regulatory compliance.
Click to read the full article.
Step-by-Step Guide to ICH Accelerated Stability Testing for Regulatory Compliance Originally published in August 2025, updated September 2025 to reflect the latest ICH Q1A(R2) accelerated stability requirements recognized by FDA, EMA, and WHO. Before the establishment of harmonized ICH guidelines, pharmaceutical stability testing was a fragmented and confusing process. Each major regulator — the FDA…
ICH Stability Testing Across Climatic Zones: A Global Compliance Roadmap Updated September 2025 — A detailed guide to navigating ICH stability requirements across global climatic zones, including WHO, FDA, EMA, CDSCO, and ANVISA perspectives. Why Climatic Zones Matter in Stability Testing Pharmaceutical stability is not only about time — it is also about geography. A…
Read More “Mapping ICH Stability Across Climatic Zones: Step-by-Step Global Compliance Guide” »